Standing reference hub
FDA Peptide Review 2026: A Dated Timeline of What Actually Changed
The coverage says two opposite things: that the FDA is about to ban BPC-157 and TB-500, or that peptides are suddenly legal again. Neither is accurate. This page is a precise, continuously dated record of the FDA 2026 peptide compounding review, stating exactly what changed, what did not, and what is still undecided.
TL;DR
On July 23-24, 2026, the FDA Pharmacy Compounding Advisory Committee (PCAC) reviews seven peptides for the 503A compounding list. It follows an April 2026 action that removed 12 peptides, including BPC-157 and TB-500, from the restricted Category 2 list, without adding them to the 503A bulks list and without making them FDA-approved. Five more peptides are deferred to a later panel before the end of February 2027.
The single most important line: the PCAC vote is advisory and non-binding. It is not a ban and not an approval, and any real change would require rulemaking that takes a year or more.
- 12
- peptides removed from Category 2 in April 2026
- 7
- under PCAC review July 23-24, 2026
- 5
- deferred to a later panel before end of Feb 2027
The timeline
Every date below is stated as precisely as the primary record allows. The most common error in the coverage is dating the Category 2 reclassification to February. The reclassification was April.
- 2023
The original restriction
The FDA placed a group of peptides on its restricted Category 2 list, citing limited human safety data. That designation ended legal 503A compounding access for substances like BPC-157 and TB-500.
- February 2026
A political signal (not the reclassification)
Health Secretary Robert F. Kennedy Jr. publicly called the 2023 restrictions an overreach, aligning with the broader Make America Healthy Again movement. This was a policy signal only. It did not, by itself, change any peptide category. Coverage that dates the reclassification to February is conflating this announcement with the April action below.
- April 15, 2026
Twelve peptides removed from Category 2
A Federal Register notice (FR Doc 2026-07361, docket FDA-2025-N-6895) removed 12 peptides, including BPC-157 and TB-500, from the restricted Category 2 "do not compound" list, effective within about seven days. Removal from Category 2 is not the same as being added to the 503A bulks list, and it is not FDA approval. This is where the regulatory gray zone begins.
- July 9, 2026
Comment cutoff for the committee
Written comments to docket FDA-2025-N-6895 received by this date are provided to the advisory committee before it meets. The docket itself remained open for the record through July 22, 2026.
- July 23-24, 2026
The PCAC reviews seven peptides
The Pharmacy Compounding Advisory Committee meets at the FDA White Oak campus in Silver Spring, Maryland, with public teleconference access, to review whether seven peptides meet the criteria for the 503A bulks list. Day 1: BPC-157, KPV, TB-500, MOTS-C. Day 2: Emideltide (DSIP), Semax, Epitalon. The committee votes on recommendations only.
- Before the end of February 2027
A second panel for the remaining five
Five of the twelve removed peptides, LL-37, GHK-Cu (injectable), Dihexa, Melanotan II, and PEG-MGF, are slated for a later PCAC meeting scheduled before the end of February 2027.
- After the votes: rulemaking horizon
Why "1+ year" is the honest estimate
A favorable committee vote is a recommendation, not a rule. Actually adding a peptide to the 503A bulks list requires formal FDA rulemaking: a proposed rule, a public comment period, and a final rule. That process routinely takes more than a year, so the realistic horizon for any practical change is late 2026 at the earliest and more likely 2027.
The twelve peptides, and where each one stands
All twelve were removed from the restricted Category 2 list in April 2026. Seven are on the July 2026 agenda; five are deferred. None is FDA-approved.
| Peptide | Removed from Category 2 | Current review status |
|---|---|---|
| BPC-157 | Yes (April 2026) | Under PCAC review, Day 1 (Jul 23) |
| KPV | Yes (April 2026) | Under PCAC review, Day 1 (Jul 23) |
| TB-500 (Thymosin Beta-4 fragment) | Yes (April 2026) | Under PCAC review, Day 1 (Jul 23) |
| MOTS-C | Yes (April 2026) | Under PCAC review, Day 1 (Jul 23) |
| Emideltide (DSIP) | Yes (April 2026) | Under PCAC review, Day 2 (Jul 24) |
| Semax | Yes (April 2026) | Under PCAC review, Day 2 (Jul 24) |
| Epitalon | Yes (April 2026) | Under PCAC review, Day 2 (Jul 24) |
| Cathelicidin LL-37 | Yes (April 2026) | Deferred to a later panel before end of Feb 2027 |
| GHK-Cu (injectable) | Yes (April 2026) | Deferred to a later panel before end of Feb 2027 |
| Dihexa | Yes (April 2026) | Deferred to a later panel before end of Feb 2027 |
| Melanotan II | Yes (April 2026) | Deferred to a later panel before end of Feb 2027 |
| PEG-MGF | Yes (April 2026) | Deferred to a later panel before end of Feb 2027 |
What each status actually means
These are the terms the coverage keeps blurring together. Plain definitions, no jargon dump.
| Term | What it means |
|---|---|
| Category 1 | A substance a compounding pharmacy may use under a valid prescription while it is being formally evaluated. Being on Category 1 is not FDA approval; it means the substance is not currently prohibited during review. |
| Category 2 | The "do not compound" list. Substances the FDA has flagged as too risky to compound, usually citing limited safety data. The 2023 peptide restriction put these compounds here. The April 2026 action removed 12 peptides from this list. |
| 503A bulks list | The specific list of bulk drug substances that licensed 503A pharmacies are cleared to compound from for individual patients. This is the list the July 2026 meeting is really about. A peptide can be off Category 2 yet still not be on this list. |
| Compounded vs. FDA-approved | A compounded drug is prepared by a licensed pharmacy for a specific patient under a prescription. An FDA-approved drug has completed formal clinical trials for a specific indication. None of the peptides in this review is FDA-approved; the question is only about the compounding pathway. |
| Advisory committee vs. final rule | The PCAC advises the FDA. Its votes are recommendations. A final rule is binding law and only exists after the FDA completes rulemaking. An advisory vote, even a unanimous one, changes nothing on its own. |
What it means for a patient today
This section is accuracy, not advice. The review is about the compounding pathway, not a consumer ban. Peptides like BPC-157 and TB-500 remain available the same way they have been: through a physician-prescribed model, where a licensed provider evaluates a patient, writes a prescription, and a licensed 503A pharmacy compounds it into a ready-to-use vial. That pathway does not depend on which federal list a peptide sits on.
Nothing about the July meeting interrupts a legitimate prescription, and there is no accurate basis for a "stock up before it is banned" urgency. The gray zone cuts both ways: these peptides are neither cleared for routine compounding nor prohibited, and none is FDA-approved. The honest summary is that access continues through licensed providers while the FDA works through a slow, technical process whose practical effects, if any, are more likely to land in 2027 than in 2026.
The accurate one-liner for reporters
The FDA did not ban these peptides and did not approve them. It removed 12 from a restricted list in April 2026 and is reviewing whether some qualify for the compounding pathway. The July vote is advisory. Any binding change is a year or more away.
Going deeper
This page is the reference timeline. For the patient-facing news read on what the meeting means and what it does not change, see the companion article, July 2026 FDA Peptide Panel: BPC-157 Review. For the broader legal picture, see are peptides legal in 2026.
Sources
Primary and government references for the facts on this page.
Frequently asked questions
Is the FDA banning peptides in July 2026?
No. The restriction happened in 2023. The July 23-24, 2026 PCAC meeting is part of the process that could restore compounding access, not a ban. In April 2026 the FDA removed 12 peptides, including BPC-157 and TB-500, from its restricted Category 2 list.
Did the FDA make these peptides legal again?
Not exactly. The April 2026 action removed 12 peptides from the restricted Category 2 list, but did not add them to the 503A bulks list and did not make them FDA-approved. They sit in a regulatory gray zone: no longer restricted, not yet cleared for routine compounding.
When did the Category 2 reclassification actually happen, February or April 2026?
April 2026. The Federal Register notice removing the 12 peptides from Category 2 (FR Doc 2026-07361, docket FDA-2025-N-6895) published on April 15, 2026. The February 2026 date some coverage cites refers to an earlier political announcement, not the actual reclassification.
Which peptides is the PCAC reviewing on July 23-24, 2026?
Seven. Day 1 (July 23): BPC-157, KPV, TB-500, and MOTS-C. Day 2 (July 24): Emideltide (DSIP), Semax, and Epitalon. Five more removed peptides (LL-37, GHK-Cu, Dihexa, Melanotan II, and PEG-MGF) are slated for a later panel before the end of February 2027.
Does a favorable vote mean I can get these peptides the next day?
No. The committee only makes recommendations. Adding a peptide to the 503A bulks list requires formal FDA rulemaking, a proposed rule, a public comment period, and a final rule, which can take more than a year.
Can I still access these peptides right now?
Patients can access them through the established medical pathway: an evaluation by a licensed provider, a prescription, and compounding by a licensed 503A pharmacy. That pathway does not depend on the category label. None of these peptides is FDA-approved.
This page is for informational purposes only and does not constitute medical or legal advice. Peptide therapy should only be pursued under the supervision of a licensed medical provider. The regulatory status described here reflects information available as of July 15, 2026 and is expected to develop around and after the July 23-24, 2026 meeting. We update this page as the process continues.
PeRx is a telehealth platform that connects patients with licensed prescribing providers. PeRx does not manufacture peptides. All peptides are compounded by licensed 503A pharmacies pursuant to patient-specific prescriptions.